1Wani MC,Taylor HL,Wall ME,et al.Plant antitumor agents VI:The isolation and structure of Taxol,a novel antileukemic and antitumor agent from Taxus brevifolia[J].J Am Chem SOC,1971,93(9):2325-2327
2Rao S,Krauss NE,Heerding JM,et al.Taxol photolabels the N-teminal 31 amino acids of p-tubulin[J].Jbiol Chem,1994,369(5):31-32
3Manfrendi JJ,Horwitz SB.Taxol:antimitotic agent with a new mechanism of action[J].Pharmacol Ther,1984,25(1):83
4Diaz JF,Andreu JM.Assembly of purified GD p-tubulinintomicrotubules induced by Taxoland Taxotere:reversibility,ligand stoichiometry,and competition[J].Bio-chemidtry,1993,31(1):27-47
5Stierle A.Taxol and taxane production by Tax-omyces and reanae,on endophytic fungus of pacifig yew[J].Science,1993,200:214-216
6Huang Y,Fang Y,Dziadyk JM,et al.The possible correlation between activation of NF-kappaB/IkappaB pathway and the susceptibility of tumor cells to paclitaxel-induced apoptosis[J].Oncol Res,2002,13(2):113-122
7Huang Y,Johnson KR,Norris JS,et al.Nuclear factor-kappaB/IkappaB signaling pathway may contribute to the mediation of paclitaxel-induced apoptosis in solid tumor cells[J].Cancer Res,2000,60(16):4426-4432
8Huang Y,Fan Y.IkappaB kinase activation is involved in regulation of paclitaxel-induced apoptosis in human tumor cell lines[J].Mol Pharmcol,2002,61(1):105-113
6[1]Seidman AD,Tiersten A,Hudis C,et al. Phase Ⅱtrial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer[J].J Clin Oncol, 1995,13(10):2 575.
7[5]Robert N,Leyland-Jones B, Asmar L,et al. Phase Ⅲ comparative study of trastuzumab and paclitaxel with and without carboplatin in patients with HER-2/neu positive advanced breast cancer[J].Breast Cancer Res Treat, 2002,76(supple): 37.
8[6]Seidman AD, Fornier MN, Esteva FJ,et al.Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification[J].J Clin Oncol,2001,19(10):2 587.
9[7]Henderson C,Berry DA,Demetri GD,et al. Improved outcomes form adding sequential paclitaxel but not form escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer[J]. J Clin Oncol,2003,21 (6): 976.
10[8]Nabholtz JM,Pienkowski T,Mackey J,et al. Phase Ⅲ trial comparing TAC (docetaxel, doxorubicin,cyclophosphamide) with FAC (5-fluorouracil,doxorubicin,cyclophospha-mide) in the adjuvant treatment of node positive breast cancer(BC)patients: interim analysis of the BCIRG 001 study[A].ASCO, 2002,21:141 abstr.
